Quick answer
SS-31 is a mitochondria-targeted peptide with laboratory, animal, and clinical-development history, but the sources collected for this article do not establish a Philippine-approved medicine or support transferring any approval to a catalog item.
They describe mitochondrial mechanisms, experiments in human tendon cells, and an animal delivery system. Those are useful evidence layers, not a complete regulatory record. Filipino readers should treat “approved,” “medicine,” and “reported” as exact legal claims that require an official current record for the named product, country, and indication.12345
What is SS-31?
SS-31 is classified as a mitochondria-targeted peptide.1 It is designed to interact with mitochondrial biology rather than acting as a general energy supplement.
Mitochondria help cells manage energy and many stress responses. A mitochondria-targeted design aims to concentrate research attention on that cellular compartment.
That description explains where researchers expect the molecule to act. It does not establish a clinical benefit, approved use, or outcome in a person.
Several reviews discuss SS-31 in settings involving mitochondrial dysfunction, inflammation, or oxidative stress.1 Reviews can map a field, but they do not replace a trial for a specific disease.
The peptide is also known in development contexts as elamipretide. A name match can help locate records, yet aliases must still be tied to the exact product and study.
This is the first boundary in its regulatory story: mechanism and naming open a research file; they do not finish a regulatory decision.
Readers researching SS-31 can view its live catalog details below. The listing identifies the catalog item and is separate from the evidence discussed here.
What did the human tendon-cell study show?
A controlled laboratory study used tendon cells obtained from people with degenerative rotator cuff tendinopathy.
Researchers reported improved measures of mitochondrial health after exposing those cells to SS-31.2
They also found a lower fraction of cells with depolarized mitochondria, which was used as a marker of mitochondrial dysfunction.6
Electron-microscope images showed changes in mitochondrial number and size after treatment.7
These are positive laboratory findings in human-derived cells. They are more directly connected to human biology than a study using only a rodent cell line.
They are still not a clinical trial in living people. Cells in a dish do not reproduce circulation, amount guidance, immune responses, whole-body safety, or patient-reported outcomes.
The accurate headline is therefore “SS-31 changed mitochondrial measures in human tendon cells,” not “SS-31 repairs tendons.”
That wording preserves the positive result without upgrading an in vitro experiment into treatment evidence.
What did animal and delivery research add?
SS-31 has also appeared as a targeting component in an experimental hydrogel system for sarcopenia research.
In that project, SS-31 helped direct a more complex payload toward muscle-cell mitochondria.3
The main intervention was not SS-31 alone. It was a multi-part delivery system that included another candidate and a hydrogel structure.
Laboratory and animal experiments reported changes in mitochondrial function and cellular senescence within that model.3
Those results belong to the complete experimental system. They cannot be transferred to a stand-alone SS-31 item.
This attribution issue resembles combination-drug research. When several active or functional components work together, the final outcome cannot be assigned to one part by assumption.
The study is relevant to SS-31’s role as a targeting tool. It does not establish treatment of sarcopenia in people or a regulatory indication.
What would prove a medicine’s regulatory status?
Regulatory status comes from an official agency record for an exact product, applicant, formulation, and use.
A journal article may discuss development history, trial results, or a commercial name. It does not itself create legal authorization.
An approval in one country also does not automatically become an approval in another. Agencies maintain their own records and may authorize different products or indications.
The Philippine verification sources cited here explain where named local records are checked; they do not themselves establish a Philippine medicine record for SS-31.
That boundary means this article cannot make a positive Philippine regulatory claim from the cited material.
A responsible regulatory story names the agency, decision date, product, applicant, indication, and current status. Without those fields, “approved” is too vague to publish as fact.
Readers comparing this topic with MOTS-c can view its live catalog details below. It is a separate catalog reference, not a suggested combination.
Why can a narrow indication not become a broad claim?
Even when an agency authorizes a medicine, the decision applies to the wording and population in the official record.
A narrow indication may name a rare condition, an age group, a diagnostic requirement, or another eligibility boundary.
It does not prove benefits for fatigue, sports recovery, healthy aging, tendinopathy, or every condition connected to mitochondria.
Mechanism makes this overreach tempting. If mitochondrial dysfunction appears across many diseases, readers may assume that one mitochondria-targeted peptide should help all of them.
That inference skips the work of clinical testing. Different diseases can involve mitochondria in different ways, and a shared cellular feature does not guarantee a shared treatment response.
Laboratory tendon findings also cannot widen a regulatory indication. They support a research question at the cell level, nothing more.267
Precise indication language protects the useful result from being diluted into a universal wellness promise.
What should Filipino readers verify?
The Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.4
Search both SS-31 and recognized aliases, then inspect the exact name, company, form, and current record.
Do not treat a licensed establishment as proof that every item it sells has a corresponding health-product authorization.
WHO explains that some falsified medical products can closely resemble genuine ones and may require quality-control analysis.8
Visual similarity, a printed certificate, or a study citation cannot confirm chemical identity. That requires traceable records and appropriate testing.
A catalog listing is also distinct from a medicine record. The card in this article identifies an item in the live catalog; it does not claim regulatory equivalence or clinical benefit.
The most reliable conclusion keeps every source, context, and product identity connected.5
How should SS-31 claims be read?
Start by placing each claim on an evidence tier.
Mechanism reviews can explain mitochondrial targeting.1 Human-cell experiments can show changes under controlled laboratory conditions.267
Animal or delivery-system studies can reveal biological possibilities but cannot establish human outcomes for SS-31 alone.3
Clinical claims require trials in living participants. Regulatory claims require canonical agency records for the named product and indication.
Then inspect the verb. “Changed a laboratory marker” is narrower than “improved symptoms,” while “authorized for a defined indication” is narrower than “approved for mitochondrial health.”
This layered approach lets readers acknowledge positive findings without blending them into a claim the source never made.
Bottom line
SS-31 is a mitochondria-targeted peptide with positive laboratory findings, including changes in mitochondrial measures in human tendon cells. It has also served as one component in an experimental animal delivery system.
Those studies help explain biological possibilities, but they do not establish treatment in living people or a Philippine regulatory indication. The cited sources do not support saying that a catalog item is an approved medicine. Filipino readers should require an official current record for the exact product, company, form, and indication before accepting any regulatory claim.
Frequently asked questions
Is SS-31 also called elamipretide?
Yes, the name appears in development contexts, but each record still needs an exact identity match.
Did the tendon study involve living patients?
No. It used human-derived tendon cells in a controlled laboratory experiment.2
Did SS-31 alone treat sarcopenia in the cited study?
No. It served as a targeting component within a multi-part experimental delivery system.3
Does a foreign approval prove Philippine authorization?
No. Philippine status requires an exact current local agency record.
Do the catalog cards make a medical claim?
No. They are neutral product-identification references, separate from the evidence.
Sources
Footnotes
-
Mitochondrial dysfunction, neuroinflammation, and associated mechanisms in sepsis-associated encephalopathy: from pathogenesis to emerging therapeutics.; Microvascular dysfunction and neurovascular signalling impairment in diabetic silent myocardial ischemia.; The Redox Revolution in Brain Medicine: Targeting Oxidative Stress with AI, Multi-Omics and Mitochondrial Therapies for the Precision Eradication of Neurodegeneration.. narrative_review ↩ ↩2 ↩3 ↩4
-
Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model.. controlled_laboratory_study This was an in vitro (cell culture) study, not a clinical trial in living humans. ↩ ↩2 ↩3 ↩4 ↩5
-
Energy-replenishing, mitochondria-targeted hydrogel microspheres mitigate sarcopenia via cellular senescence amelioration.. laboratory_and_animal_research SS-31 was a targeting ligand in a complex hydrogel microsphere, not the primary therapeutic agent being tested. ↩ ↩2 ↩3 ↩4 ↩5
-
Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Official Philippine regulatory verification service. A portal record applies to the exact product or establishment named in that record. ↩ ↩2
-
Mitochondrial dysfunction, neuroinflammation, and associated mechanisms in sepsis-associated encephalopathy: from pathogenesis to emerging therapeutics.; Microvascular dysfunction and neurovascular signalling impairment in diabetic silent myocardial ischemia.; The Redox Revolution in Brain Medicine: Targeting Oxidative Stress with AI, Multi-Omics and Mitochondrial Therapies for the Precision Eradication of Neurodegeneration.; Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model.; Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Editorial synthesis of the canonical research records and Philippine verification sources. This synthesis is educational and is not personal medical advice or a product recommendation. ↩ ↩2
-
Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model.. controlled_laboratory_study This was an in vitro (cell culture) study, not a clinical trial in living humans. ↩ ↩2 ↩3
-
Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model.. controlled_laboratory_study This was an in vitro (cell culture) study, not a clinical trial in living humans. ↩ ↩2 ↩3
-
WHO laboratory analysis of suspected falsified medical products; WHO laboratory testing for health-product regulation. WHO guidance on suspected falsified medical products and regulatory laboratory testing. Appearance alone cannot authenticate a product or establish a research outcome. ↩
